Literature DB >> 12107345

Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma.

M Korabiowska1, I Ruschenburg, H Betke, J Stachura, T Schlott, C C Cardo, U Brinck.   

Abstract

The retinoblastoma gene is a cell cycle regulator preventing cells from entering into S-phase. An altered expression of the retinoblastoma gene has been reported in the majority of human malignancies. The main aim of this study was to investigate retinoblastoma gene expression in the full spectrum of melanoma progression from naevus to melanoma metastases by applying immunohistochemistry and RT-PCR. All naevi with and without dysplasia showed high expression of the retinoblastoma gene. In primary melanomas, Rb-positive cells were found in 82 out of 106. Loss of expression correlated with an increase in Clark level and shorter survival rates. An independent prognostic role of the retinoblastoma gene was confirmed by Cox multivariate analyses (p < 0.01). In melanoma metastases, retinoblastoma gene expression (at the RNA level) was found in 18 out of 26 melanoma lymphatic metastases, and in 2 out of 5 liver metastases. Our results indicate a downregulation of the retinoblastoma gene in the progression of melanocytic tumours. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12107345     DOI: 10.1159/000064338

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  4 in total

Review 1.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 2.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

4.  Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.

Authors:  Shinji Mizuarai; Takumitsu Machida; Tsutomu Kobayashi; Hideya Komatani; Hiraku Itadani; Hidehito Kotani
Journal:  Mol Cancer       Date:  2011-03-29       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.